Brief: China NT Pharma Group Sees Consol Loss For FY
Jan 30 (Reuters) - China NT Pharma Group Co Ltd 1011.HK :
* GROUP IS EXPECTED TO RECORD CONSOLIDATED LOSS FOR YEAR
ENDED 31
DECEMBER 2018
* EXPECTED RESULT DUE TO NET LOSS FROM CHANGE IN FAIR VALUE
OF
FINANCIAL LIABILITIES OF CONVERTIBLE PREFERENCE SHARES IN
COMPANY
Source text for Eikon: ID:nHKSc6Lqs2
Further company coverage: 1011.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China NT Pharma Co
See all newsBrief: China NT Pharma Group Says Expected Loss For Year Further Reduced By HK$15.4 Million As Compared With Prior Guidance
Brief: China Nt Pharma Expects Net Loss Attributable Of RMB25 MLN To RMB30 MLN In FY
Brief: China NT Pharma Makes Application For Resumption Of Trading On Feb 11
Brief: HKEX Says Trading In Shares Of China NT Pharma Group Company Halted
Brief: China Nt Pharma Group Says To Issue Bonds In Aggregate Principal Amount Of HK$65 Million